Diabetes & metabolism journalJul 15, 2026

Semaglutide and Exercise Together Help Keep Muscle and Reveal Organ Communication in Obesity

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 16, 2026

Abstract

Semaglutide promotes weight loss and improves metabolic parameters in individuals with obesity.

The use of semaglutide is associated with reductions in lean mass.
Concerns exist regarding the long-term impact of semaglutide on muscle health.
Combining semaglutide with exercise may help preserve muscle mass.
The combination could also enhance metabolic outcomes.

Simplified

Semaglutide, a glucagon-like peptide-1 receptor agonist, effectively promotes weight loss and improves metabolic parameters in individuals with obesity. However, its use is often accompanied by reductions in lean mass, raising concerns about long-term muscle health. This study explored whether combining semaglutide with exercise could preserve muscle mass and enhance metabolic outcomes.

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

GLP-1 Therapies

GLP-1 TherapiesIssue #46

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

yesterday7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

1 week ago7 studies

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

2 weeks ago7 studies

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

3 weeks ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

4 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

5 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

6 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

7 weeks ago7 studies

Two-thirds of patients kept weight off after stopping GLP-1 drugs

8 weeks ago7 studies

Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months

10 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief